Valneva SE (VALN) Shares Outstanding (2019 - 2026)
Valneva SE (VALN) posted Shares Outstanding (Entity) of $84.1 million for Q4 2025, down 1.18% sequentially from $85.1 million in Q2 2025, and up 15.42% YoY from $72.9 million in Q4 2024.
Valneva SE (VALN) Shares Outstanding (2019 - 2026) Analysis & Trends
Valneva SE has reported Shares Outstanding (Entity) for 7 years, with the latest figure at $84.1 million in Q4 2025.
- Quarterly Shares Outstanding (Entity) rose 15.42% year-over-year to $84.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $84.1 million (up 15.42% YoY) and the FY2025 annual result came in at $84.1 million, up 15.42% from the prior year.
- Shares Outstanding (Entity) fell to $84.1 million in Q4 2025 per VALN's latest filing, from $85.1 million in the prior quarter.
- Over five years, Shares Outstanding (Entity) peaked at $85.1 million in Q2 2025 and troughed at $45.9 million in Q1 2021.
- A 5-year average of $62.4 million and a median of $58.7 million in 2022 frame the typical range for Shares Outstanding (Entity).
- The sharpest annual moves came in 2023 and 2024: Shares Outstanding (Entity) climbed 20.05% in 2023, then grew 5.11% in 2024.
- Over 5 years, Shares Outstanding (Entity) stood at $48.8 million in 2021, then rose by 18.29% to $57.7 million in 2022, then climbed by 20.05% to $69.3 million in 2023, then grew by 5.11% to $72.9 million in 2024, then advanced by 15.42% to $84.1 million in 2025.
- According to Business Quant data, Shares Outstanding (Entity) over the past three periods registered $84.1 million, $85.1 million, and $72.9 million for Q4 2025, Q2 2025, and Q4 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 62.19 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 210.89 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.45 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 25.05 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 445.06 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 133.61 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 217.35 Mn |
| 10 | Valneva SE | 618.67 Mn | 477.41 Mn | 1.86 Mn | 168.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 168.18 Mn |
| Mar 31, 2026 | 168.18 Mn |
| Dec 31, 2025 | 168.18 Mn |
| Sep 30, 2025 | 145.71 Mn |
| Jun 30, 2025 | 145.71 Mn |
| Mar 31, 2025 | 145.71 Mn |
| Dec 31, 2024 | 145.71 Mn |
| Sep 30, 2024 | 138.62 Mn |
| Jun 30, 2024 | 138.62 Mn |
| Mar 31, 2024 | 138.62 Mn |
| Dec 31, 2023 | 138.62 Mn |
| Sep 30, 2023 | 115.47 Mn |
| Jun 30, 2023 | 115.47 Mn |
| Mar 31, 2023 | 115.47 Mn |
| Dec 31, 2022 | 115.47 Mn |
| Sep 30, 2022 | 97.62 Mn |
| Jun 30, 2022 | 97.62 Mn |
| Mar 31, 2022 | 97.62 Mn |
| Dec 31, 2021 | 97.62 Mn |
| Sep 30, 2021 | 90.76 Mn |